LFCRLFCRHealthcare · Drug Manufacturers - Specialty & Generic

LFCR Stock Forecast: Lifecore Biomedical, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$6.40
+0.16% on the day

The 5 Wall Street analysts covering Lifecore Biomedical, Inc. hold a median 12-month price target of $6.28 — -1.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 17 Nov 2026 — in the weakest quartile.

Market cap
$243.2M
Ticker Nerd rank
2/ 100
Median analyst target
$6.28
Analysts covering
5
Revenue$34.2M−2.8% y/y
Operating income$2.6M
Net income−$6.2M
Free cash flow−$2.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
0.0%
1M
+0.3%
YTD
−21.8%
1Y
−15.8%
From 52W high
−27.4%
From 52W low
+74.9%
$3.66
$8.82
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LFCR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lifecore Biomedical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
2/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
63
Revisions
37
Momentum
31
Volatility
20
Growth
8
Accruals
7
Issuance
1
Value
1
Quality
0

Size (63): Smaller than most of the companies we track.

Quality (0): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LFCR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LFCR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$3.00$4.00$5.00$6.00$7.00$8.00$9.00Jan 26Apr 26Jul 26Oct 26LFCRHigh $6.28Median $6.28Low $6.28

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
0 Buy5 Hold0 Sell
Low $6.28Median $6.28High $6.28

The green dot is the last close — the median target sits −1.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 Sept 2026Barrington ResearchDowngradeMarket Perform—
28 Sept 2026William BlairDowngradeMarket Perform—
16 June 2026Barrington ResearchMaintainsOutperform—
16 June 2026Barrington ResearchMaintainsOutperform$6.00 → $6.50
29 Apr 2026Barrington ResearchMaintainsOutperform—
27 Mar 2026Barrington ResearchMaintainsOutperform—
24 Mar 2026Barrington ResearchMaintainsOutperform—
17 Mar 2026Barrington ResearchUpgradeOutperform—
4 Sept 2025KeybancInitiatesSector Weight—
21 May 2025William BlairInitiatesOutperform—
3 Jan 2025Stephens & Co.ReiteratesEqual-Weight—
22 Nov 2024Craig-HallumMaintainsBuy—
5 Sept 2024Craig-HallumInitiatesBuy—
28 Aug 2024Barrington ResearchDowngradeMarket Perform—
1 Sept 2023Barrington ResearchMaintainsOutperform—
1 Sept 2023Stephens & Co.MaintainsEqual-Weight—
2 June 2023Barrington ResearchMaintainsOutperform—
24 May 2023Barrington ResearchMaintainsOutperform—
21 Mar 2023Barrington ResearchMaintainsOutperform—
20 Mar 2023Barrington ResearchMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

LFCR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LFCR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Lifecore Biomedical, Inc. returned −15.8% against +12.2% for the S&P 500, dividends included.

LFCR vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26LFCRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LFCR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Lifecore Biomedical, Inc. (LFCR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
56.2×

Cheaper than 12% of US stocks

Price / sales
2.3×

Cheaper than 46% of US stocks

Price / book
−7.1×

Cheaper than 98% of US stocks

EV / EBITDA
104.0×

Cheaper than 2% of US stocks

Growth & margins
Revenue growth (YoY)
−18.6%

Higher than 12% of US stocks

Earnings growth (YoY)
−2.8%

Higher than 34% of US stocks

Gross margin
35.3%

Higher than 42% of US stocks

Operating margin
−6.2%

Higher than 27% of US stocks

Net margin
−66.8%

Higher than 8% of US stocks

Returns & dividend
Return on equity
312.3%

Higher than 99% of US stocks

Return on assets
−19.1%

Higher than 20% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Lifecore Biomedical, Inc. (LFCR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Lifecore Biomedical, Inc. has a market value of $243.2M and an enterprise value of $433.6M.

  • Revenue in the twelve months to 30 June 2026: $124.9M. The latest quarter shrank 18.6% year on year.

  • Net income over the same four quarters: −$32.3M, a −25.8% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.97.

  • Free cash flow in the twelve months to 30 June 2026: $4.2M.

  • Shares outstanding: 37.7M.

  • Trailing P/E: 56.2×; forward P/E: −8.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Lifecore Biomedical, Inc. employs 382 people — $327K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 16 Nov 2026

Data provided by Twelve Data

Peers

LFCR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
LFCRLifecore Biomedical, Inc.$243.2M2
BIOABioAge Labs, Inc.$226.3M16
EBSEmergent BioSolutions, Inc.$290.4M80
SIGASIGA Technologies, Inc.$195.6M51
ADCTADC Therapeutics SA$189.9M86
ANIKAnika Therapeutics, Inc.$172.2M98
TLRYTilray Brands, Inc.$347.3M16

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lifecore Biomedical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LFCR news & analysis

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR)

GlobeNewsWire · 11 Nov 2026neutral

Brodsky & Smith announced that it is reminding investors about an investigation involving Lifecore Biomedical, alongside investigations involving three other companies. The announcement provides contact information for shareholders who wish to discuss the investigation.

Why it matters — LFCR shareholders may want to note the announced investigation and the firm's invitation to contact it for discussion.

Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update

GlobeNewsWire · 4 Nov 2026positive

Lifecore Biomedical announced financial results for the third quarter and nine months ended September 30, 2026, and provided a corporate update. The release highlighted multiple new business wins and a growing pipeline.

Why it matters — LFCR watchers may note the reported period results and the company's update on new business wins and pipeline growth.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR)

GlobeNewsWire · 30 Oct 2026neutral

Brodsky & Smith announced an investigation involving Lifecore Biomedical, alongside investigations involving ADT, RXO and PTC. The notice invites shareholders to contact the firm to discuss the investigation.

Why it matters — LFCR shareholders may wish to note that the company is named in the law firm's investigation notice.

Lifecore Biomedical to Participate at Upcoming Industry Conferences

GlobeNewsWire · 7 Oct 2026neutral

Lifecore Biomedical announced it will participate in three upcoming industry events. The excerpt does not identify the events.

Why it matters — LFCR watchers may note the company’s upcoming industry-event participation, though the excerpt provides no further details.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR), WaFd, Inc. (Nasdaq – WAFD)

GlobeNewsWire · 5 Oct 2026negative

Brodsky & Smith, a law firm, issued a shareholder update reminding investors of investigations it is conducting into several companies, including Lifecore Biomedical, Inc. (Nasdaq – LFCR). The firm invites shareholders to discuss the matter at no cost or financial obligation.

Why it matters — LFCR watchers would care because the firm's announcement indicates an active shareholder investigation into the company, which could draw attention to governance or disclosure concerns.

FAQ

Frequently asked questions about LFCR stock

What is the LFCR stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Lifecore Biomedical, Inc. have a median 12-month price target of $6.28, with estimates ranging from $6.28 to $6.28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LFCR stock a buy right now?

Of the 5 analysts covering Lifecore Biomedical, Inc., 0 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lifecore Biomedical, Inc. 2 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LFCR?

As at 17 Nov 2026, Lifecore Biomedical, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (63 of 100).

Will LFCR stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies -1.9% from the last close, and Ticker Nerd's factor model ranks Lifecore Biomedical, Inc. 2 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LFCR stock forecast for 2030?

No analyst covering Lifecore Biomedical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LFCR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6.28 to $6.28 over the next 12 months.

How has LFCR stock performed over the past year?

Lifecore Biomedical, Inc. returned -15.8% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lifecore Biomedical, Inc. do?

Lifecore Biomedical Inc. is a contract development and manufacturing organization focused on sterile injectable pharmaceuticals and medical device products.

What is the latest news on LFCR?

The most recent item we track (GlobeNewsWire, 11 Nov 2026): "BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR)". Brodsky & Smith announced that it is reminding investors about an investigation involving Lifecore Biomedical, alongside investigations involving three other companies. The announcement provides contact information for shareholders who wish to discuss the investigation.

Company

About Lifecore Biomedical, Inc.

Lifecore Biomedical Inc. is a contract development and manufacturing organization focused on sterile injectable pharmaceuticals and medical device products. The company provides development, aseptic fill-finish, and commercial manufacturing services for products packaged in syringes, vials, and cartridges. It also produces pharmaceutical-grade hyaluronic acid, a biomaterial used in a range of medical applications, including ophthalmic and orthopedic products. Lifecore Biomedical Inc. serves pharmaceutical and medical device customers that need regulated manufacturing expertise, formulation support, and process scale-up capabilities. Headquartered in Chaska, Minnesota, the company operates in the biopharmaceutical manufacturing and biomaterials markets, where it plays a specialized role in supporting complex injectable therapies and related healthcare products.

CEO Mr. Paul Josephs · 382 employees · United States · https://www.lifecore.com